抗發炎治療藥物市場規模、佔有率和成長分析（按藥物類別、適應症、應用、通路和地區分類）－2025-2032年產業預測

預計到 2023 年，全球抗發炎治療市場規模將達到 1,024 億美元，到 2024 年將達到 1,073.2 億美元，到 2032 年將達到 1,561.5 億美元，預測期（2025-2032 年）的複合年成長率為 4.8%。

受類風濕性關節炎、氣喘和發炎性腸道疾病（IBD）等自體免疫疾病和慢性發炎性疾病盛行率上升的推動，全球抗發炎治療市場正經歷顯著成長。醫療系統持續面臨的壓力凸顯了創新治療方法的必要性。生物製藥和標靶治療已顯著改善患者預後，而生物相似藥的推出則加劇了市場競爭並降低了成本，從而擴大了先進療法的可及性。隨著人口老化導致慢性發炎患者數量不斷增加，預計對這些治療方法的需求將進一步成長。此外，眾多針對白血球白細胞介素路徑的研究生物製藥展現出良好的前景，為精準醫療的發展鋪平了道路，並鞏固了長期的市場潛力。

全球抗發炎治療市場促進因素

全球抗發炎治療市場的發展主要受自體免疫疾病和慢性發炎性疾病（例如發炎性腸道疾病、乾癬、氣喘和類風濕性關節炎）日益普遍的推動。關節炎等疾病患者數量的顯著成長，推動了對先進治療方案的需求。不斷擴大的患者群體凸顯了有效治療方法的必要性，並促進了生物製劑和生物相似藥在全球範圍內的應用和普及。隨著人們對這些複雜疾病的認知不斷提高，市場正積極響應，推出創新解決方案，以滿足尋求緩解持續性發炎症狀的患者的多樣化需求。

限制全球抗發炎治療市場發展的因素

生物製藥的高昂價格是患者獲得治療的一大障礙，尤其是中低收入國家。像阿達木單抗（Humira）這樣的生物製藥，每位患者每年的費用可能高達7.2萬美元，這對許多患者來說難以負擔。即使是通常被視為更具成本效益的替代療法的生物相似藥，也仍然面臨著同樣的經濟挑戰。此外，保險覆蓋範圍的不平衡和冗長的報銷流程加劇了這種情況，限制了世界各地患者獲得所需治療的機會。因此，這些經濟和製度上的障礙正在阻礙全球抗發炎治療的整體療效。

全球抗發炎藥物市場趨勢

全球抗發炎治療市場正經歷著向靶向生物製藥和先進小分子化合物開發方向的重大轉變。 IL-23抑制劑、JAK抑制劑和FcRn標靶抗體等創新藥物正在取代傳統的廣譜免疫抑制劑。這一趨勢反映了治療適應症的策略性擴張，從小眾自體免疫疾病擴展到潰瘍性大腸炎等更常見的疾病，從而在提高療效的同時最大限度地減少副作用。隨著重磅藥物面臨來自學名藥和生物相似藥日益激烈的競爭，這種多元化不僅增強了市場潛力，也促使企業提供更多專業化且具有商業性價值的治療方案。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

抗發炎治療藥物市場規模（依藥物類別分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 抗發炎生技藥品
• 非類固醇消炎劑（NSAIDs）
• 皮質類固醇

抗發炎治療藥物市場規模（按適應症和複合年成長率分類）（2025-2032 年）

• 市場概覽
• 關節炎
• 呼吸系統疾病
• 多發性硬化症
• 銀屑病
• 發炎性腸道疾病

抗發炎治療藥物市場規模（依應用領域分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 自體免疫疾病
• 發炎性疾病
• 呼吸系統疾病

抗發炎治療藥物市場規模（依分銷管道分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 醫院藥房
• 零售藥房

抗發炎治療藥物市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2024 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2024 年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2022-2024年營收年比比較

主要企業簡介

• AbbVie（USA）
• Johnson & Johnson（USA）
• Pfizer（USA）
• F. Hoffmann-La Roche（Switzerland）
• Novartis（Switzerland）
• Merck & Co., Inc.（USA）
• AstraZeneca（UK/Sweden）
• Bristol Myers Squibb（USA）
• Amgen（USA）
• Eli Lilly and Company（USA）
• Sanofi（France）
• GSK（GlaxoSmithKline）（UK）
• Bayer（Germany）
• Gilead Sciences（USA）
• Takeda Pharmaceutical Company（Japan）
• Teva Pharmaceutical Industries（Israel）
• Boehringer Ingelheim（Germany）
• Regeneron Pharmaceuticals（USA）
• Viatris（USA）
• UCB（Belgium）

結論與建議

Global Anti-Inflammatory Therapeutics Market size was valued at USD 102.4 billion in 2023 and is poised to grow from USD 107.32 billion in 2024 to USD 156.15 billion by 2032, growing at a CAGR of 4.8% during the forecast period (2025-2032).

The global market for anti-inflammatory therapeutics is experiencing significant growth driven by the rising prevalence of autoimmune and chronic inflammatory diseases like rheumatoid arthritis, asthma, and inflammatory bowel disease (IBD). The persistent burden on healthcare systems underscores the need for innovative treatment options. Biologics and targeted therapies have significantly enhanced patient outcomes, while the introduction of biosimilars promotes competition and decreases costs, making advanced treatments more accessible. As the aging population continues to experience chronic inflammation, demand for these therapies is expected to rise. Furthermore, numerous pipeline biologics targeting interleukin pathways indicate a promising future, paving the way for advancements in precision medicine and solidifying long-term market potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti-Inflammatory Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti-Inflammatory Therapeutics Market Segments Analysis

Global Anti-Inflammatory Therapeutics Market is segmented by Drug Class, Indication, Application, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids. Based on Indication, the market is segmented into Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis and Inflammatory Bowel Disease. Based on Application, the market is segmented into Autoimmune, Inflammatory Diseases and Respiratory Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is driven by the increasing prevalence of autoimmune and chronic inflammatory diseases such as inflammatory bowel disease, psoriasis, asthma, and rheumatoid arthritis. The significant rise in the number of individuals affected by conditions like arthritis has led to heightened demand for advanced therapeutic options. This growing patient population underscores the necessity for effective treatments, fueling the acceptance and utilization of biologics and biosimilars on a global scale. As awareness of these complex conditions expands, the market responds with innovative solutions aimed at addressing the diverse needs of patients seeking relief from persistent inflammatory ailments.

Restraints in the Global Anti-Inflammatory Therapeutics Market

The high cost of biologic treatments presents a significant barrier to access for patients, particularly in low- and middle-income nations. Biologics like Humira can reach annual costs of up to USD 72,000 for a single patient, making them prohibitively expensive for many individuals. This affordability challenge persists even for biosimilars, which are often intended to be more cost-effective alternatives. Additionally, discrepancies in insurance coverage and protracted reimbursement processes exacerbate the situation, limiting patient access to necessary care across various global regions. Consequently, these financial and systemic hurdles hinder the overall effectiveness of anti-inflammatory therapeutics on a global scale.

Market Trends of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is experiencing a significant shift towards the development of targeted biologics and sophisticated small molecules. Innovations such as IL-23 inhibitors, JAK inhibitors, and FcRn-targeting antibodies are increasingly replacing traditional broad-spectrum immunosuppressants. This trend reflects a strategic expansion of therapeutic applications, moving from niche autoimmune disorders to common conditions like ulcerative colitis, enhancing therapeutic efficacy while minimizing side effects. As blockbuster drugs face intensified competition from generics and biosimilars, this diversification not only elevates the market potential but also drives companies to deliver more specialized and commercially valuable treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Anti-Inflammatory Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-Inflammatory Biologics
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids

Global Anti-Inflammatory Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Arthritis
• Respiratory Diseases
• Multiple Sclerosis
• Psoriasis
• Inflammatory Bowel Disease

Global Anti-Inflammatory Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Autoimmune
• Inflammatory Diseases
• Respiratory Diseases

Global Anti-Inflammatory Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy

Global Anti-Inflammatory Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Application, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK (GlaxoSmithKline) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations